CA3091783A1 - Compounds that modulates ampa receptor function - Google Patents
Compounds that modulates ampa receptor function Download PDFInfo
- Publication number
- CA3091783A1 CA3091783A1 CA3091783A CA3091783A CA3091783A1 CA 3091783 A1 CA3091783 A1 CA 3091783A1 CA 3091783 A CA3091783 A CA 3091783A CA 3091783 A CA3091783 A CA 3091783A CA 3091783 A1 CA3091783 A1 CA 3091783A1
- Authority
- CA
- Canada
- Prior art keywords
- compound
- alkyl
- mmol
- disorder
- treatment
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/553—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Psychiatry (AREA)
- General Chemical & Material Sciences (AREA)
- Hospice & Palliative Care (AREA)
- Pain & Pain Management (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB1803340.7A GB201803340D0 (en) | 2018-03-01 | 2018-03-01 | Compounds |
| GB1803340.7 | 2018-03-01 | ||
| PCT/GB2019/050578 WO2019166822A1 (en) | 2018-03-01 | 2019-03-01 | Compounds that modulates ampa receptor function |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA3091783A1 true CA3091783A1 (en) | 2019-09-06 |
Family
ID=61903711
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA3091783A Pending CA3091783A1 (en) | 2018-03-01 | 2019-03-01 | Compounds that modulates ampa receptor function |
Country Status (16)
| Country | Link |
|---|---|
| US (3) | US11298345B2 (https=) |
| EP (1) | EP3759092B1 (https=) |
| JP (1) | JP7225255B2 (https=) |
| KR (2) | KR20250093578A (https=) |
| CN (1) | CN112004811B (https=) |
| AU (1) | AU2019226718C1 (https=) |
| BR (1) | BR112020017739A2 (https=) |
| CA (1) | CA3091783A1 (https=) |
| DK (1) | DK3759092T3 (https=) |
| ES (1) | ES2970784T3 (https=) |
| FI (1) | FI3759092T3 (https=) |
| GB (1) | GB201803340D0 (https=) |
| MX (1) | MX2020009097A (https=) |
| PL (1) | PL3759092T3 (https=) |
| RU (1) | RU2020127537A (https=) |
| WO (1) | WO2019166822A1 (https=) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB201702221D0 (en) | 2017-02-10 | 2017-03-29 | Univ Of Sussex | Compounds |
| GB201803340D0 (en) | 2018-03-01 | 2018-04-18 | Univ Of Sussex | Compounds |
Family Cites Families (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TW575561B (en) | 1999-03-25 | 2004-02-11 | Hoffmann La Roche | 1-arenesulfonyl-2-aryl-pyrrolidine and piperidine derivatives |
| IL152848A0 (en) | 2000-06-12 | 2003-06-24 | Eisai Co Ltd | 1,2-dihydropyridine derivatives, pharmaceutical compositions containing the same and methods for the production thereof |
| RU2279428C2 (ru) | 2000-09-18 | 2006-07-10 | Эйсай Ко., Лтд. | Производные пиридазинона и триазинона и их применение в качестве фармацевтических препаратов |
| AU2003302027A1 (en) | 2002-11-21 | 2004-06-15 | Vicore Pharma Ab | New tricyclic angiotensin ii agonists |
| JP5289043B2 (ja) | 2005-04-12 | 2013-09-11 | ヴィコール・ファルマ・アーベー | 新規な三環系アンジオテンシンｉｉアゴニスト |
| CA2646585A1 (en) | 2006-03-20 | 2007-09-27 | Glaxo Group Limited | Compounds which potentiate ampa receptor and uses thereof in medicine |
| EP2049475B1 (en) | 2006-04-24 | 2012-02-01 | Eli Lilly & Company | Cyclohexyl substituted pyrrolidinones as inhibitors of 11-beta-hydroxysteroid dehydrogenase 1 |
| TW200817385A (en) | 2006-07-04 | 2008-04-16 | Organon Nv | Heterocyclic derivatives |
| DE602007013450D1 (de) | 2006-11-03 | 2011-05-05 | Glaxo Group Ltd | Verbindungen, die den ampa-rezeptor verstärken, und deren anwendung in der medizin |
| GB0711088D0 (en) | 2007-06-08 | 2007-07-18 | Glaxo Group Ltd | Compounds |
| GB0711089D0 (en) | 2007-06-08 | 2007-07-18 | Glaxo Group Ltd | Compounds |
| EP2183228B1 (en) | 2007-07-26 | 2014-08-20 | Vitae Pharmaceuticals, Inc. | CYCLIC INHIBITORS OF 11ß -HYDROXYSTERIOD DEHYDROGENASE 1 |
| KR20100063087A (ko) | 2007-09-20 | 2010-06-10 | 코텍스 파마슈티칼스, 인크. | 글루타메이트 시냅스 반응 향상을 위한 3-치환된 1,2,3-트리아진-4-온 및 3-치환된 1,3-피리미디논 |
| GB0721094D0 (en) | 2007-10-26 | 2007-12-05 | Glaxo Group Ltd | Compounds |
| TW200934497A (en) | 2007-11-13 | 2009-08-16 | Organon Nv | Heterocyclic derivatives |
| AR071236A1 (es) | 2008-05-01 | 2010-06-02 | Vitae Pharmaceuticals Inc | Inhibidores ciclicos de la 11beta-hidroxiesteroide deshidrogenasa 1 |
| TW201012803A (en) | 2008-06-06 | 2010-04-01 | Organon Nv | Heterocyclic derivatives |
| TW201031649A (en) | 2008-12-02 | 2010-09-01 | Organon Nv | 1-(4-(pyridin-2-yl)benzyl)imidazolidine-2,4-dione derivatives |
| AP3066A (en) | 2009-06-26 | 2014-12-31 | Pfizer | Heterocyclic sulfonamides, uses and pharmaceuticalcompositions thereof |
| WO2011132051A2 (en) * | 2010-04-19 | 2011-10-27 | Glenmark Pharmaceuticals S.A. | Tricycle compounds as phosphodiesterase-10 inhibitors |
| UY33930A (es) | 2011-03-04 | 2012-10-31 | Novartis Ag | Inhibidores novedosos de quinasas |
| GB201702221D0 (en) | 2017-02-10 | 2017-03-29 | Univ Of Sussex | Compounds |
| GB201803340D0 (en) | 2018-03-01 | 2018-04-18 | Univ Of Sussex | Compounds |
-
2018
- 2018-03-01 GB GBGB1803340.7A patent/GB201803340D0/en not_active Ceased
-
2019
- 2019-03-01 CA CA3091783A patent/CA3091783A1/en active Pending
- 2019-03-01 CN CN201980016394.0A patent/CN112004811B/zh active Active
- 2019-03-01 MX MX2020009097A patent/MX2020009097A/es unknown
- 2019-03-01 DK DK19710107.4T patent/DK3759092T3/da active
- 2019-03-01 US US16/970,394 patent/US11298345B2/en active Active
- 2019-03-01 JP JP2020544266A patent/JP7225255B2/ja active Active
- 2019-03-01 WO PCT/GB2019/050578 patent/WO2019166822A1/en not_active Ceased
- 2019-03-01 ES ES19710107T patent/ES2970784T3/es active Active
- 2019-03-01 KR KR1020257019599A patent/KR20250093578A/ko active Pending
- 2019-03-01 AU AU2019226718A patent/AU2019226718C1/en active Active
- 2019-03-01 PL PL19710107.4T patent/PL3759092T3/pl unknown
- 2019-03-01 RU RU2020127537A patent/RU2020127537A/ru unknown
- 2019-03-01 FI FIEP19710107.4T patent/FI3759092T3/fi active
- 2019-03-01 KR KR1020207025799A patent/KR102821949B1/ko active Active
- 2019-03-01 BR BR112020017739-3A patent/BR112020017739A2/pt unknown
- 2019-03-01 EP EP19710107.4A patent/EP3759092B1/en active Active
-
2022
- 2022-03-04 US US17/687,296 patent/US12383540B2/en active Active
-
2025
- 2025-06-13 US US19/238,079 patent/US20250375432A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| NZ767186A (en) | 2025-02-28 |
| US12383540B2 (en) | 2025-08-12 |
| US11298345B2 (en) | 2022-04-12 |
| AU2019226718A8 (en) | 2020-09-24 |
| WO2019166822A1 (en) | 2019-09-06 |
| KR102821949B1 (ko) | 2025-06-16 |
| FI3759092T3 (fi) | 2024-01-18 |
| ES2970784T3 (es) | 2024-05-30 |
| JP2021515749A (ja) | 2021-06-24 |
| AU2019226718B2 (en) | 2023-09-28 |
| PL3759092T3 (pl) | 2024-04-08 |
| KR20200128032A (ko) | 2020-11-11 |
| BR112020017739A2 (pt) | 2020-12-22 |
| EP3759092B1 (en) | 2023-12-20 |
| KR20250093578A (ko) | 2025-06-24 |
| US20250375432A1 (en) | 2025-12-11 |
| JP7225255B2 (ja) | 2023-02-20 |
| CN112004811B (zh) | 2023-09-22 |
| RU2020127537A (ru) | 2022-04-26 |
| GB201803340D0 (en) | 2018-04-18 |
| AU2019226718A1 (en) | 2020-09-03 |
| MX2020009097A (es) | 2020-10-08 |
| US20230000847A1 (en) | 2023-01-05 |
| US20210113539A1 (en) | 2021-04-22 |
| DK3759092T3 (da) | 2024-01-22 |
| CN112004811A (zh) | 2020-11-27 |
| EP3759092A1 (en) | 2021-01-06 |
| AU2019226718C1 (en) | 2024-01-11 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN104870448B (zh) | 三唑并吡嗪 | |
| US20250375432A1 (en) | Compounds that modulates ampa receptor function | |
| US20140088151A1 (en) | Alhydroxymethyl biaryl benzotriazole derivatives | |
| TW201605827A (zh) | 新穎雙－醯胺吡啶 | |
| CN109071434A (zh) | 酰基磺酰胺NaV1.7抑制剂 | |
| AU2018218307C1 (en) | AMPA receptor potentiators | |
| HK40044378B (en) | Compounds that modulates ampa receptor function | |
| HK40044378A (en) | Compounds that modulates ampa receptor function | |
| CA3051647C (en) | Ampa receptor potentiators | |
| EP2457906A1 (en) | Derivatives of 1,2,4-benzothiadiazine dioxide, their preparation and use as allosteric modulators of the AMPA receptor | |
| WO2016020784A1 (en) | N-acylpyrrolidine ether tropomyosin-related kinase inhibitors | |
| BR112019016603B1 (pt) | Composto, uso deste e uma formulação farmacéutica |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request |
Effective date: 20240301 |
|
| MFA | Maintenance fee for application paid |
Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 6TH ANNIV.) - STANDARD Year of fee payment: 6 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20250221 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT DETERMINED COMPLIANT Effective date: 20250221 Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20250221 |
|
| P11 | Amendment of application requested |
Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT RECEIVED - VOLUNTARY AMENDMENT Effective date: 20250225 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT Effective date: 20250228 |
|
| P11 | Amendment of application requested |
Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT DETERMINED COMPLIANT Effective date: 20250311 |
|
| P13 | Application amended |
Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P13-X000 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPLICATION AMENDED Effective date: 20250311 |
|
| D15 | Examination report completed |
Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D15-D126 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: EXAMINER'S REPORT Effective date: 20250402 |
|
| P11 | Amendment of application requested |
Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT RECEIVED - RESPONSE TO EXAMINER'S REQUISITION Effective date: 20250731 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT Effective date: 20250807 |
|
| P11 | Amendment of application requested |
Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT DETERMINED COMPLIANT Effective date: 20250911 |
|
| P13 | Application amended |
Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P13-X000 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPLICATION AMENDED Effective date: 20250911 |
|
| R11 | Change to the name of applicant or owner or transfer of ownership requested |
Free format text: ST27 STATUS EVENT CODE: A-2-2-R10-R11-R127 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: TRANSFER RECORDAL REQUEST OR RESPONSE Effective date: 20250911 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT Effective date: 20250911 |
|
| R14 | Transfer of ownership recorded |
Free format text: ST27 STATUS EVENT CODE: A-2-2-R10-R14-R129 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: TRANSFER REQUIREMENTS DETERMINED COMPLIANT Effective date: 20250912 |
|
| MFA | Maintenance fee for application paid |
Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 7TH ANNIV.) - STANDARD Year of fee payment: 7 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20260224 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20260224 |